Robert J Romanelli1, Qiwen Huang2, Joseph Lacy3, Lobat Hashemi4, Alana Wong4, Alden Smith4. 1. Sutter Health, Palo Alto Medical Foundation Research Institute, Center for Health Systems Research, Palo Alto, CA, USA. romanerj1@sutterhealth.org. 2. Sutter Health, Palo Alto Medical Foundation Research Institute, Center for Health Systems Research, Palo Alto, CA, USA. 3. Department of Neurology, Sutter Health, Palo Alto Foundation Medical Group, Palo Alto, CA, USA. 4. Sanofi Genzyme, Cambridge, MA, USA.
Abstract
BACKGROUND: Research is needed to examine differences in multiple sclerosis (MS) prevalence by race-ethnicity. The goal of this study was to quantify MS prevalence in a health care system in Northern California and examine differences in prevalence and phenotype by race-ethnicity. METHODS: We conducted a retrospective, observational cohort study of adults (2010-2016). MS prevalence estimates were standardised to distributions of gender and race-ethnicity for the underlying geographic region and stratified by gender and race-ethnicity with age adjustment. We performed a chart review of a racial-ethnic stratified sample of patients to examine disease phenotypes. RESULTS: 1,058,102 patients were identified, of which 3286 had MS. The overall direct-standardised prevalence was 288.0 cases per 100,000 population (95% confidence interval: 276.3-299.8). Age-adjusted prevalence ranged from 677.0 per 100,000 among non-Hispanic black women to 49.7 per 100,000 among non-Hispanic Asian men. Non-Hispanic blacks compared with other groups more often had primary-progressive (10.0% vs. 0.0-4.0%) or progressive-relapsing MS (6.0% vs. 0.0-2.0%). CONCLUSIONS: In this Northern Californian Cohort, between 2010 and 2016 the direct-standardised MS prevalence was estimated at 288.0 per 100,000 population, and increased over time. Non-Hispanic blacks, especially women, were disproportionately affected and had less common, earlier progressive MS phenotypes.
BACKGROUND: Research is needed to examine differences in multiple sclerosis (MS) prevalence by race-ethnicity. The goal of this study was to quantify MS prevalence in a health care system in Northern California and examine differences in prevalence and phenotype by race-ethnicity. METHODS: We conducted a retrospective, observational cohort study of adults (2010-2016). MS prevalence estimates were standardised to distributions of gender and race-ethnicity for the underlying geographic region and stratified by gender and race-ethnicity with age adjustment. We performed a chart review of a racial-ethnic stratified sample of patients to examine disease phenotypes. RESULTS: 1,058,102 patients were identified, of which 3286 had MS. The overall direct-standardised prevalence was 288.0 cases per 100,000 population (95% confidence interval: 276.3-299.8). Age-adjusted prevalence ranged from 677.0 per 100,000 among non-Hispanic black women to 49.7 per 100,000 among non-Hispanic Asian men. Non-Hispanic blacks compared with other groups more often had primary-progressive (10.0% vs. 0.0-4.0%) or progressive-relapsing MS (6.0% vs. 0.0-2.0%). CONCLUSIONS: In this Northern Californian Cohort, between 2010 and 2016 the direct-standardised MS prevalence was estimated at 288.0 per 100,000 population, and increased over time. Non-Hispanic blacks, especially women, were disproportionately affected and had less common, earlier progressive MS phenotypes.
Entities:
Keywords:
Electronic health records; Multiple sclerosis; Real-world; race-ethnic disparities
Authors: Annette F Okai; Annette M Howard; Mitzi J Williams; Justine D Brink; Chiayi Chen; Tamela L Stuchiner; Elizabeth Baraban; Grace Jeong; Stanley L Cohan Journal: Neurology Date: 2022-04-25 Impact factor: 11.800
Authors: Annette M Langer-Gould; Edlin Grisell Gonzales; Jessica B Smith; Bonnie H Li; Lorene M Nelson Journal: Neurology Date: 2022-05-03 Impact factor: 11.800